Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

the PREVENT Study Group

Research output: Contribution to journalArticlepeer-review


During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD.; PREVENT: NCT01892345; open-label extension: NCT02003144.

Original languageEnglish (US)
Pages (from-to)480-486
Number of pages7
JournalMultiple Sclerosis Journal
Issue number3
StatePublished - Mar 2022


  • Clinical trial
  • neuromyelitis optica (NMO)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension'. Together they form a unique fingerprint.

Cite this